NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
15/11/2024
Voltar para busca
Dado oficial do USPTO
DAEWOONG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
15/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35
Data de depósito
27/04/2017
Data de registro
06/11/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/11/2024
Última transação
15/11/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Seongnam-si, Gyeonggi, KR
Examinador
MMEJE, OBIEZE GINIKANWA
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
DAEWOONG CO., LTD.
Representantes
Bryant E. Wade/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Classificação técnica
Classes Nice
Classe 5Classe 35
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsacetaminophenacne medicationsacne treatment preparationsadrenal hormone preparationsalcohol for topical useallergy relief medicationsanalgesicsandrogen preparationsanesthetics for surgical and non-surgical useantacidsfungicidesantiarrhythmicsantibioticsanticoagulantsanticonvulsantsantidepressantsantidiabetic preparationsantiviralsanti-cancer preparationsanti-infectivesanti-inflammatoriesantipyretic preparationsantibacterial pharmaceuticalscalcium channel blockersbeta blockersdrug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparationsdrug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparationseye dropseye patches for medical purposeshair growth stimulantsvaccinesadjuvants for use with vaccinesdiureticsamino acids for medical purposes; dietary and nutritional supplements; medicated skin lotions ; bandages for skin wounds; vitamin and mineral preparations for medical use; biological preparations for medical purposes for use in the treatment of the central nervous systemdiabetesskin disorderswoundseye diseases and conditionsswelling in the legsrespiratory diseasesasthmaerectile dysfunctioncardiovascular conditionsheart rhythm disorders and infectious diseases; all-purpose disinfecting preparations; pharmaceutical preparations for use in cardiovascular treatment; diagnostic preparations for medical purposes; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical agents affecting digestive organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for treating wounds; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations to prevent swelling in the legs; pharmaceutical preparations for treating respiratory diseases and asthma; pharmaceutical preparations for the treatment of erectile dysfunction; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; plant extracts for pharmaceutical purposes adapted for use in the treatment of the central nervous systemdiabetesskin disorderswoundseye diseases and conditionsswelling in the legsrespiratory diseasesasthmaerectile dysfunctioncardiovascular conditionsheart rhythm disorders and infectious diseases; plant extracts for pharmaceutical purposes adapted for use in chemotherapy; veterinary preparations for treatment of intestinal bacteria in mammals; veterinary vaccines; sanitary preparations for medical use; medical dressings
Classe 35
Wholesale and retail store services featuring pharmaceutical and veterinary preparations; wholesale and retail store services featuring dietary supplements; wholesale and retail store services featuring cosmetics; procurement services for others purchasing pharmaceuticals for human and veterinary purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
15/11/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/11/2024
E815
TEAS SECTION 8 & 15 RECEIVED
31/05/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/11/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/11/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/08/2018
PUBO
PUBLISHED FOR OPPOSITION
21/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/07/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/06/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/06/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/05/2018
GNRT
NON-FINAL ACTION E-MAILED
28/05/2018
CNRT
NON-FINAL ACTION WRITTEN
28/05/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/05/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/05/2018
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
30/04/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
08/03/2018
GNSL
LETTER OF SUSPENSION E-MAILED
08/03/2018
CNSL
SUSPENSION LETTER WRITTEN
08/03/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/02/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/02/2018
ALIE
ASSIGNED TO LIE
01/02/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/01/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
31/07/2017
GNRT
NON-FINAL ACTION E-MAILED
31/07/2017
CNRT
NON-FINAL ACTION WRITTEN
31/07/2017
DOCK
ASSIGNED TO EXAMINER
25/07/2017
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/05/2017
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/05/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/05/2017
NWAP
NEW APPLICATION ENTERED
01/05/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace DAEWOONG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.